CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets

3.3. TOP PLAYER POSITIONING, 2016
3.4. MARKET DYNAMICS

3.4.1. Drivers

3.4.1.1. Rise in number of surgeries
3.4.1.2. Increase in the incidence rate of diabetes
3.4.1.3. Growth in geriatric population

3.4.2. Restrains

3.4.2.1. Side effects of gastroparesis drugs
3.4.2.2. Time-consuming regulatory process

3.4.3. Opportunities

3.4.3.1. Presence of untapped market
3.4.3.2. Strong pipeline for gastroparesis drugs

3.4.4. Impact analysis

3.5. CLINICAL TRIALS
3.6. PATENT ANALYSIS

3.6.1. Patent analysis, by year

CHAPTER 4 GASTROPARESIS DRUGS MARKET, BY DRUG CLASS

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. PROKINETIC AGENTS

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. ANTIEMETIC AGENTS

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. BOTULINUM TOXIN INJECTIONS

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

CHAPTER 5 GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. DIABETIC GASTROPARESIS

5.2.1. Market size and forecast

5.3. IDIOPATHIC GASTROPARESIS

5.3.1. Market size and forecast

5.4. POST-SURGICAL GASTROPARESIS

5.4.1. Market size and forecast

5.5. OTHERS

5.5.1. Market size and forecast

CHAPTER 6 GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. HOSPITALS

6.2.1. Market size and forecast

6.3. PHARMACIES

6.3.1. Market size and forecast

6.4. CLINICS

6.4.1. Market size and forecast

6.5. E-COMMERCE

6.5.1. Market size and forecast

CHAPTER 7 GASTROPARESIS DRUGS MARKET, BY REGION

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. North America gastroparesis drugs market, by country

7.2.3.1. Market size and forecast

7.2.4. U.S.

7.2.4.1. U.S. gastroparesis drugs market, by drug class
7.2.4.2. U.S. gastroparesis drugs market, by disease type
7.2.4.3. U.S. gastroparesis drugs market, by distribution channel

7.2.5. Canada

7.2.5.1. Canada gastroparesis drugs market, by drug class
7.2.5.2. Canada gastroparesis drugs market, by disease type
7.2.5.3. Canada gastroparesis drugs market, by distribution channel

7.2.6. Mexico

7.2.6.1. Mexico gastroparesis drugs market, by drug class
7.2.6.2. Mexico gastroparesis drugs market, by disease type
7.2.6.3. Mexico gastroparesis drugs market, by distribution channel

7.2.7. North America gastroparesis drugs market, by drug class
7.2.8. North America gastroparesis drugs market, by disease type
7.2.9. North America gastroparesis drugs market, by distribution channel

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Europe gastroparesis drugs market, by country
7.3.4. Market size and forecast
7.3.5. Germany

7.3.5.1. Germany gastroparesis drugs market, by drug class
7.3.5.2. Germany gastroparesis drugs market, by disease type
7.3.5.3. Germany gastroparesis drugs market, by distribution channel

7.3.6. France

7.3.6.1. France gastroparesis drugs market, by drug class
7.3.6.2. France gastroparesis drugs market, by disease type
7.3.6.3. France gastroparesis drugs market, by distribution channel

7.3.7. UK

7.3.7.1. UK gastroparesis drugs market, by drug class
7.3.7.2. UK gastroparesis drugs market, by disease type
7.3.7.3. UK gastroparesis drugs market, by distribution channel

7.3.8. Italy

7.3.8.1. Italy gastroparesis drugs market, by drug class
7.3.8.2. Italy gastroparesis drugs market, by disease type
7.3.8.3. Italy gastroparesis drugs market, by distribution channel

7.3.9. Spain

7.3.9.1. Spain gastroparesis drugs market, by drug class
7.3.9.2. Spain gastroparesis drugs market, by disease type
7.3.9.3. Spain gastroparesis drugs market, by distribution channel

7.3.10. Rest of Europe

7.3.10.1. Rest of Europe gastroparesis drugs market, by drug class
7.3.10.2. Rest of Europe gastroparesis drugs market, by disease type
7.3.10.3. Rest of Europe gastroparesis drugs market, by distribution channel

7.3.11. Europe gastroparesis drugs market, by drug class
7.3.12. Europe gastroparesis drugs market, by disease type
7.3.13. Europe gastroparesis drugs market, by distribution channel

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Asia-Pacific gastroparesis drugs market, by country

7.4.3.1. Market size and forecast

7.4.4. Japan

7.4.4.1. Japan gastroparesis drugs market, by drug class
7.4.4.2. Japan gastroparesis drugs market, by disease type
7.4.4.3. Japan gastroparesis drugs market, by distribution channel

7.4.5. China

7.4.5.1. China gastroparesis drugs market, by drug class
7.4.5.2. China gastroparesis drugs market, by disease type
7.4.5.3. China gastroparesis drugs market, by distribution channel

7.4.6. Australia

7.4.6.1. Australia gastroparesis drugs market, by drug class
7.4.6.2. Australia gastroparesis drugs market, by disease type
7.4.6.3. Australia gastroparesis drugs market, by distribution channel

7.4.7. India

7.4.7.1. India gastroparesis drugs market, by drug class
7.4.7.2. India gastroparesis drugs market, by disease type
7.4.7.3. India gastroparesis drugs market, by distribution channel

7.4.8. South Korea

7.4.8.1. South Korea gastroparesis drugs market, by drug class
7.4.8.2. South Korea gastroparesis drugs market, by disease type
7.4.8.3. South Korea gastroparesis drugs market, by distribution channel

7.4.9. Rest of Asia-Pacific

7.4.9.1. Rest of Asia-Pacific gastroparesis drugs market, by drug class
7.4.9.2. Rest of Asia-Pacific gastroparesis drugs market, by disease type
7.4.9.3. Rest of Asia-Pacific gastroparesis drugs market, by distribution channel

7.4.10. Asia-Pacific gastroparesis drugs market, by drug class
7.4.11. Asia-Pacific gastroparesis drugs market, by disease type
7.4.12. Asia-Pacific gastroparesis drugs market, by distribution channel

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. LAMEA gastroparesis drugs market, by country
7.5.4. Market size and forecast
7.5.5. Brazil

7.5.5.1. Brazil gastroparesis drugs market, by drug class

7.5.6. Brazil gastroparesis drugs market, by disease type

7.5.6.1. Brazil gastroparesis drugs market, by distribution channel

7.5.7. Saudi Arabia

7.5.7.1. Saudi Arabia gastroparesis drugs market, by drug class
7.5.7.2. Saudi Arabia gastroparesis drugs market, by disease type
7.5.7.3. Saudi Arabia gastroparesis drugs market, by distribution channel

7.5.8. South Africa

7.5.8.1. South Africa gastroparesis drugs market, by drug class
7.5.8.2. South Africa gastroparesis drugs market, by disease type
7.5.8.3. South Africa gastroparesis drugs market, by distribution channel

7.5.9. Rest of LAMEA

7.5.9.1. Rest of LAMEA gastroparesis drugs market, by drug class
7.5.9.2. Rest of LAMEA gastroparesis drugs market, by disease type
7.5.9.3. Rest of LAMEA gastroparesis drugs market, by distribution channel

7.5.10. LAMEA gastroparesis drugs market, by drug class
7.5.11. LAMEA gastroparesis drugs market, by disease type
7.5.12. LAMEA gastroparesis drugs market, by distribution channel

CHAPTER 8 COMPANY PROFILES

8.1. ABBOTT LABORATORIES (ABBOTT ARZNEIMITTEL GMBH)

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance

8.2. ALLERGAN PLC

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments

8.3. ASTRAZENECA PLC

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance

8.4. CADILA PHARMACEUTICALS LIMITED

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio

8.5. ETX PHARMA, INC.

8.5.1. Company overview
8.5.2. Company Snapshot
8.5.3. Product portfolio

8.6. EVOKE PHARMA, INC.

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Product portfolio
8.6.4. Business performance

8.7. GLAXOSMITHKLINE PLC

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance

8.8. NEUROGASTRX, INC.

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Product portfolio

8.9. THERAVANCE BIOPHARMA, INC.

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments

8.10. VALEANT PHARMACEUTICAL INTERNATIONAL, INC.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments